Canntab Therapeutics
For Immediate Release
2020_05_15
Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
TORONTO, May 15th, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab’s strategic research and partnership program, and overseeing the Company’s ongoing manufacturing and distribution operations.
Mr. Laxminarayan is a pharmaceutical scientist with a successful history of bringing to market a number of pharmaceutical drugs throughout a career spanning over 25 years. Mr. Laxminarayan began his career in India, as a bench chemist, and most recently acted in a consultant role to the Company, as Director of Quality Assurance & Quality Control, where he assisted with the research and development needed to formulate the Company’s current product line. His expertise in nano emulsion, extended release, and poorly soluble drug development, has played a crucial role in the Company’s research and development with respect to cannabis oil inputs.
“Joshi has played an integral part in helping Canntab strengthen its competitive position and relevance, and distinguish itself in the pharmaceutical industry. His appointment as CSO is expected to evolve as we continue manufacturing, into a position where he can oversee not only our ongoing Research & Development, but also our day to day manufacturing and distribution operations,” explains Jeff Renwick, Co-founder and CEO of Canntab. Mr. Renwick continues, “As Canntab enters the next phase of its growth, Mr. Laxminarayan will be invaluable to our continued success, driving us closer to our goal of being the world leader in solid oral dose therapeutic cannabis solutions.”
About Canntab Therapeutics
Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.
Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.
Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
For further information:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
+1 833-301-3812
jeff@canntab.ca
Richard Goldstein
Chief Financial Officer
+1 833-301-3812
richard@canntab.ca
Whoever is careless with the truth in small matters cannot be trusted with important matters.
– Albert Einstein
